Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape - Philip Kantoff ...

Decipher mRNA Score for Prediction of Survival Benefit from Docetaxel at Start of Androgen Deprivation Therapy for Advanced Prostate Cancer: An Ancillary Study of the STAMPEDE Docetaxel Trials Ruth ...

(UroToday.com) The 2024 South Central AUA annual meeting included an endourology session, featuring a presentation by Dr.

The 2024 South Central AUA annual meeting included a session on lower genitourinary tract cancer, featuring a presentation by Dr. Peter Sullivan discussing financial toxicity in testicular cancer ...

The 2024 South Central AUA annual meeting included a session on lower genitourinary tract cancer, featuring a presentation by Anish Patel discussing 90-day urologic complications from pelvic ...

(UroToday.com) The 2024 South Central AUA annual meeting included a session on prostate cancer, featuring a presentation by Dr. Gal Saffati discussing a systematic review regarding whether veterans ...

SUVmax cut point of 9 is associated with a: 33-fold higher risk of high risk pathology in radical prostatectomy specimens with a PPV of 81% 24-fold higher risk of high risk disease features in radical ...

The 2024 South Central AUA annual meeting included the Sushil Lacy manuscript competition, featuring a presentation by Dr. Amanda Myers discussing the elucidation of response rates to additional BCG ...

Patients were further queried to identify those who received adequate BCG induction (defined as ≥ 5 weekly instillations). They then summarized the distribution of this group and the treatments ...

This study included a review of consecutive patients diagnosed with NMIBC between January 2005 and May 2023 to identify ...

Additionally, it is the only nephron sparing approach that offers relative oncologic certainty by yielding complete pathological information about the excised tumor. Indeed, we know that partial ...

Nivolumab and ipilimumab (NIVO+IPI) is standard therapy for patients with intermediate and poor risk advanced renal cell carcinoma (RCC). However, the efficacy and safety of NIVO+IPI in elderly ...